Streetbeat News

Stock Prices

ETCUSD

Ethereum Classic (CRYPTO: ETC) is trading higher by 7.2% to $38.06, largely in response to Bitcoin reaching a new all-time high of $72,000. The price movement of Bitcoin often influences other cryptocurrencies, including Ethereum Classic, due to increased public awareness and the correlation between their market dynamics.

Portfolio Pulse from Henry Khederian

March 11, 2024 | 6:13 pm

MRNA

Moderna shares are trading higher following the announcement of a new Phase 2/3 trial of pembrolizumab (Keytruda) by Merck in combination with Moderna's V940 for cutaneous squamous cell carcinoma. The trial's posting on clinicaltrials.gov and Jefferies' positive outlook on the program's investment and confidence have contributed to the optimism.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:09 pm

MRK

MRNA

Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) are collaborating on a new clinical trial for V940, an individualized neoantigen therapy, combined with pembrolizumab for treating advanced cutaneous squamous cell carcinoma. The Phase 2 trial will evaluate the safety and efficacy of this combination compared to standard care. The trial is expected to start next month and conclude by 2029. Analysts from Jefferies and RBC Capital have expressed positive views on this development, highlighting the potential of the therapy and the growing incidence of cSCC. MRNA shares rose 8.96% to $112.26.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 6:09 pm

MRNA

Moderna's shares are up due to the announcement of a new Phase 2/3 trial for pembrolizumab (Keytruda) plus Moderna's V940 in cutaneous squamous cell carcinoma, as listed on clinicaltrials.gov. Jefferies' commentary on the trial suggests increased investment and confidence in the program.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:07 pm

CLPT

ClearPoint Neuro (NASDAQ:CLPT) is scheduled to release its quarterly earnings report on 2024-03-12, with analysts expecting an EPS of $-0.20. Investors are hopeful for a beat on this estimate and positive guidance for future growth. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat followed by a 17.71% drop. Shares are currently trading at $6.19, down 22.78% over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

NATR

Natures Sunshine Products (NASDAQ:NATR) is scheduled to release its quarterly earnings report on March 12, 2024, with an estimated EPS of $0.15. Analysts and investors are particularly interested in the company's guidance for future growth. Historical data shows mixed stock price reactions to past earnings reports. Shares have seen a significant increase of 75.76% over the last 52 weeks, trading at $17.85 as of March 08.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

PFMT

Performant Financial (NASDAQ:PFMT) is scheduled to release its quarterly earnings report on March 12, 2024. Analysts predict an EPS of $0.00. The company's past performance shows a pattern of beating EPS estimates, which has occasionally led to significant share price movements. Shares are currently trading at $3.0, reflecting a 4.1% decline over the last year. Investors will be particularly attentive to the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

REFI

Chicago Atlantic Real (NASDAQ:REFI) is scheduled to release its quarterly earnings report on March 12, 2024. Analysts predict an EPS of $0.51. The company's historical performance shows mixed results with both earnings beats and misses, leading to varied stock price reactions. Shares have increased by 25.54% over the last 52 weeks, indicating a positive outlook from long-term shareholders. Investors will be keenly watching for the earnings outcome and any forward guidance provided.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

NOTE

FiscalNote Holdings (NYSE:NOTE) is scheduled to release its quarterly earnings report on 2024-03-12, with analysts expecting an EPS of $-0.15. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing a drop in share price the following day. Shares are currently trading at $2.15, up 21.1% over the last 52 weeks. Investors will be keenly watching for the earnings outcome and particularly the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

CRMD

Cormedix (NASDAQ:CRMD) is scheduled to release its quarterly earnings report on March 12, 2024, with analysts expecting an EPS of $-0.20. Historical data shows that the company's stock price reacts more significantly to guidance than to earnings beats or misses. Last quarter, Cormedix beat the EPS estimate, resulting in a 6.39% increase in its share price. Over the past year, CRMD shares have decreased by 6.13%, indicating potential concern among long-term investors ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm